Related references
Note: Only part of the references are listed.Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study
Doron Aronson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2011)
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
James E. Udelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Non-peptide arginine-vasopressin antagonists: the vaptans
Guy Decaux et al.
LANCET (2008)
Hyponatremia treatment guidelines 2007: Expert panel recommendations
Joseph G. Verbalis et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
James E. Udelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
Mihai Gheorghiade et al.
EUROPEAN HEART JOURNAL (2007)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
Marvin A. Konstam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
WT Abraham et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
LC Costello-Boerrigter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Vasopressin antagonism in heart failure
SR Goldsmith et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
M Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Vasopressin: A new target for the treatment of heart failure
CR Lee et al.
AMERICAN HEART JOURNAL (2003)
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure -: Results from a double-blind, randomized trial
M Gheorghiade et al.
CIRCULATION (2003)
Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
JE Udelson et al.
CIRCULATION (2001)
Share Paper
